Resistance to targeted therapies for tumours with MET exon 14 skipping mutations or MET amplifications have been described, including bypass track alterations in both the MAPK and PI3K pathways, as well as the emergence of solvent front mutations and other alterations impacting the binding of type I inhibitors.6, 24, 31, 32, 53, 54, 55, 56, 57, 58, 59. The gene discussed is MET; the disease is neoplasm.